Invivyd (NASDAQ:IVVD) Given Buy Rating at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Invivyd (NASDAQ:IVVD) in a report published on Thursday morning,Benzinga reports. They currently have a $9.00 target price on the stock.

Several other research analysts also recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Invivyd in a research note on Monday, February 24th. Morgan Stanley dropped their target price on Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research note on Wednesday, November 20th. Four investment analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $7.89.

Invivyd Trading Up 2.6 %

IVVD opened at $0.74 on Thursday. The firm has a market cap of $88.35 million, a price-to-earnings ratio of -0.38 and a beta of 0.09. Invivyd has a 12 month low of $0.35 and a 12 month high of $4.74. The stock has a fifty day moving average price of $0.97 and a 200-day moving average price of $0.87.

Insider Buying and Selling at Invivyd

In other Invivyd news, Director Terrance Mcguire sold 83,817 shares of the business’s stock in a transaction dated Thursday, December 26th. The stock was sold at an average price of $0.54, for a total transaction of $45,261.18. Following the sale, the director now owns 3,340,520 shares in the company, valued at approximately $1,803,880.80. The trade was a 2.45 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In the last 90 days, insiders have sold 246,138 shares of company stock worth $120,902. 17.90% of the stock is currently owned by insiders.

Institutional Trading of Invivyd

Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC grew its stake in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company’s stock valued at $52,000 after purchasing an additional 87,358 shares during the last quarter. Barclays PLC grew its stake in Invivyd by 179.6% during the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Invivyd during the 4th quarter valued at about $74,000. JPMorgan Chase & Co. boosted its stake in shares of Invivyd by 644.1% in the fourth quarter. JPMorgan Chase & Co. now owns 256,900 shares of the company’s stock worth $114,000 after buying an additional 222,375 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its stake in shares of Invivyd by 1,276.5% in the fourth quarter. Two Sigma Advisers LP now owns 304,200 shares of the company’s stock worth $135,000 after buying an additional 282,100 shares during the last quarter. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.